Domo signs strategic collaboration agreement with AWS for AI solutions
Robert W. Selander, a director at HealthEquity, Inc. (NASDAQ:HQY), recently sold shares of the company's stock, according to a filing with the Securities and Exchange Commission. On April 9, Selander sold a total of 5,750 shares, with prices ranging from $76.79 to $78.81 per share, generating approximately $446,512 in total proceeds. The sale comes as HealthEquity trades at a P/E ratio of 71.8x, with the stock down about 17% year-to-date, according to InvestingPro data.
Earlier on the same day, Selander exercised stock options to acquire 12,500 shares at a price of $28.68 each, totaling $358,500. Following these transactions, Selander now holds 84,969 shares of HealthEquity common stock. Despite recent market volatility, InvestingPro analysis shows the company maintains a GREAT financial health score, with liquid assets exceeding short-term obligations and moderate debt levels.
The transactions were made under a Rule 10b5-1 trading plan, which Selander adopted in July 2024. For deeper insights into insider trading patterns and 12 additional exclusive ProTips about HealthEquity, check out the company's comprehensive Pro Research Report on InvestingPro.
In other recent news, HealthEquity, Inc. reported its fourth-quarter earnings for fiscal year 2025, revealing a revenue of $311.8 million, which marked a 19% increase year-over-year and exceeded analyst expectations. However, the company's non-GAAP earnings per share (EPS) of $0.69 fell short of projections. Analysts from BTIG maintained a Buy rating with a $130 price target, while KeyBanc and JMP Securities both adjusted their price targets to $110, citing ongoing costs due to fraud challenges. Despite these challenges, HealthEquity's management remains focused on addressing fraud and enhancing security measures, as highlighted in their recent earnings call. Raymond (NSE:RYMD) James upgraded HealthEquity's stock rating to Strong Buy, expressing confidence in the company's ability to manage fraud-related issues effectively. HealthEquity has also been proactive in launching new products, such as AI-driven benefits tools, which are expected to support future growth. The company's strong cash generation and market share gains in the Health Savings Accounts (HSA) sector continue to bolster investor confidence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.